Introduction
============

Epithelial ovarian cancer (EOC) is a major cause of cancer-related mortality among gynecologic malignancies. Based on the fact that EOC frequently remains clinically silent, most patients have microscopically or macroscopically metastatic peritoneal lesions at diagnosis ([@b1-or-40-01-0195]). However, EOC is in general a heterogeneous tumor that contains various histologic types, including serous, clear-cell, endometrioid, mucinous and other types of adenocarcinoma. The clinical outcomes and biological hallmarks are different among these histological subtypes. This diversity makes it complicated to understand and analyze EOC ([@b2-or-40-01-0195]). Ovarian clear-cell carcinoma (CCC) is a comparatively rare tumor in Western countries, representing less than 10% of all epithelial ovarian cancer (EOC) cases diagnosed ([@b3-or-40-01-0195]). However, the incidence of this tumor was estimated to make it a common pathological type among EOC cases in East Asia ([@b4-or-40-01-0195]). In particular, CCC is the second most frequent subtype of EOC, accounting for 24.8% of all malignant ovarian neoplasms diagnosed in Japan ([@b5-or-40-01-0195]). Clinically, this tumor is known to be diagnosed at an early stage, and shows frequent unilateral occurrence, association with endometriosis, and comorbidity with thromboembolism ([@b3-or-40-01-0195],[@b6-or-40-01-0195]--[@b8-or-40-01-0195]). In addition, based on recent larger-scale studies, a poorer oncologic outcome is exhibited by patients with advanced-stage CCC compared with those with a serous histology, reflecting its potential chemoresistance to conventional platinum-based compounds ([@b9-or-40-01-0195],[@b10-or-40-01-0195]). Therefore, it is crucial to determine prognostic biomarkers of CCC to develop strategies for improving the clinical outcome and/or monitoring the tumor status.

Kinesin family member 20A (KIF20A), a member of the kinesin superfamily-6, is a microtubule-associated motor protein that is required for cell cycle mitosis ([@b11-or-40-01-0195],[@b12-or-40-01-0195]). This molecule was initially revealed to localize to the Golgi apparatus and participate in organelle dynamics by interacting with the GTP-bound form of Rab6 ([@b13-or-40-01-0195]). In non-cancerous normal tissues, KIF20A is reported to be expressed in fetal liver, adult bone marrow and thymus, whereas low levels are found in the placenta and heart ([@b14-or-40-01-0195],[@b15-or-40-01-0195]). On the other hand, according to previous studies, it was shown to be overexpressed in various malignancies, including lung and breast cancer ([@b15-or-40-01-0195],[@b18-or-40-01-0195]). With regard to malignant cellular functions, KIF20A has been reported to be involved in proliferation, migration, invasiveness and angiogenesis ([@b15-or-40-01-0195],[@b19-or-40-01-0195]--[@b21-or-40-01-0195]). In addition, a recent study also demonstrated the possible involvement of KIF20A in the resistance of breast cancer to paclitaxel ([@b22-or-40-01-0195]). From the clinical point of view, KIF20A expression was found to be associated with poor oncologic outcome in a number of human malignancies, including breast, nasopharyngeal, hepatocellular and uterine cervical carcinoma ([@b23-or-40-01-0195]--[@b26-or-40-01-0195]).

To the best of our knowledge, no published study has examined KIF20A expression in ovarian CCC. These clinical and molecular backgrounds led us to hypothesize that KIF20A plays a central role in the progression of CCC, and that positive KIF20A expression may be a valuable indicator to predict an unfavorable oncologic outcome in patients with CCC. In the present study, we explored the relationship between KIF20A expression and the prognosis of ovarian CCC patients, and we analyzed the functions of KIF20A in CCC cell growth.

Materials and methods
=====================

### Cell culture

One human pancreatic cancer cell line (PANC1: positive control) ([@b15-or-40-01-0195]) and seven EOC cell lines (ES-2, TOV-21G, RMG-I, RMG-II, SKOV3, OV-90 and KOC-7C) were maintained in RPMI-1640 medium with 10% fetal bovine serum (FBS) and penicillin/streptomycin. These cell lines except for RMG-I and RMG-II cells were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA) in 2012-2013. RMG-I and RMG-II cells were generously donated by Fujita Health University (Toyoake, Japan). These cell lines were maintained in RPMI-1640 medium (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany) supplemented with 10% FBS and penicillin-streptomycin at 37°C in a humidified atmosphere of 5% CO~2~.

### Inhibition of KIF20A by small interfering RNA (siRNA)

To produce KIF20A-knockdown cells, ES-2 and SKOV3 cells were transfected with either a pool of small interfering RNA (siRNA) oligonucleotides specific to human KIF20A (final concentration, 50 nmol/l; sc-91657; Santa Cruz Biotechnology, Santa Cruz, CA, USA) or control siRNA (5′-CUUACGCUGAGUACUUCGATT-3′: Sigma-Aldrich; Merck KGaA) using GenePORTER 2 Transfection reagent (Gene Therapy Systems Inc., San Diego, CA, USA). KIF20A siRNA (sc-91657) is a pool of 3 different siRNA duplexes: sc-91657A (sense, 5′-CUGUGAAGGAGAUGGUAAATT-3′), sc-91657B (sense, 5′-GCAAUCCCUAUGUGAAAGATT-3′) and sc-91657C (sense, 5′-GUUCCUGCAUGAUUGUCAATT-3′). After overnight incubation at 37°C, the culture medium was replaced with fresh complete medium containing 10% FBS. Cells were harvested after 48 h and solubilized for western blot analysis of KIF20A silencing.

### Western blot analysis

To examined the expression of KIF20A in seven EOC cell lines (CCC: ES-2, TOV-21G, RMG-I, RMG-II, KOC-7C cells: non-CCC SKOV3, OV-90 cells) or knockdown efficacy of the siRNA experiment (ES-2 and SKOV3 cells), western blotting was performed. The experimental procedure of western blotting was previously described ([@b27-or-40-01-0195]). As primary antibodies, we used anti-KIF20A (diluted 1:100; cat. no. sc-374508; Santa Cruz Biotechnology) and anti-β-actin antibodies (diluted 1:3,000; cat. no. 017-24573; Wako Pure Chemical Industries Ltd., Osaka, Japan). The primary antibodies were washed in 0.05% Tween-20/PBS, and then incubated with horseradish peroxidase-conjugated secondary antibody (diluted 1:3,000; cat. no. A90-116P; Bethyl Laboratories Inc., Montgomery, TX, USA). Proteins were visualized using enhanced chemiluminescence reagent (Amersham Pharmacia Biotech, Piscataway, NJ, USA). The ratio of the intensity of KIF20A-positive bands to the intensity of β-actin-positive ones was used to compare the relative expression levels of these proteins in the KIF20A- and control-siRNA transfected lines. The intensities of the bands were semi-quantified by ImageJ software (version 1.51k; National Institutes of Health, Bethesda, MD, USA) (<https://imagej.nih.gov/ij/>).

### Cell proliferation assay

To determine the effect of KIF20A on cell proliferation, ES2 and SKOV3 cells transfected with KIF20A-siRNA or control siRNA were seeded onto 96-well plates at a density of 1×10^3^ cells/well. Then, at time-points of 0, 24, 48 and 72 h, the cell viability rate was assessed using Cell Counting Kit-8 (CCK-8; Dojindo Molecular Technologies, Inc., Rockville, MD, USA). Ten microliters of CCK-8 solution was added to each well and the cells were incubated for another 2 h and then a microplate reader (ELx808; BioTek Instruments Japan, Tokyo, Japan) was used to measure the absorbance of each well at 450 nm. All experiments were independently repeated three times. Paprotrain (Tocris Bioscience, Bristol, UK) is a cell-permeable acrylonitrile compound that inhibits the kinesin-6 family member KIF20A. We investigated the effect of Paprotrain on cell proliferation using pretreatment at doses of 0, 25 and 100 µM in the ES2 and SKOV3 cells.

### Apoptosis assay

The percentage of apoptotic cells was assayed using the Annexin V-FLUOS Staining kit (Roche Life Science, Indianapolis, IN, USA). Briefly, 1×10^5^ ES-2 cells were seeded in 6-well plates and cultured for 24 h. The cells were collected and resuspended in 100 µl of binding buffer. Then, the cells were incubated with 5 µl of FITC-Annexin V in the dark for 15 min at room temperature. Subsequently, 5 µl of PI was added and incubated with the cells for 20 min at room temperature in the dark. Finally, the cell samples were examined in a flow cytometer. Each assessment of proliferation and apoptosis was repeated three times.

### Cell cycle distribution

For cell cycle analysis, ES2 and SKOV3 cells were treated with or without S109 for 24 h. Then, the cells were collected, fixed in 70% ethanol, washed twice with phosphate-buffered saline (PBS), and then stained with propidium iodide (PI) solution containing 25 µg/ml of RNAse and 50 µg/ml of PI in the dark for 30 min. Subsequently, the cells were assayed with FACSCalibur (Becton-Dickinson, Franklin Lakes, NJ, USA) and analyzed using CellQuest Pro software (Becton-Dickinson).

### Patients and immunohistochemical staining

Forty-three human ovarian CCC tissues were obtained from patients who underwent surgical treatment at the Nagoya University Hospital between 1993 and 2006 after providing informed consent. To ascertain the histological types, we adopted the World Health Organization (WHO) classification criteria. The clinical stage was assigned according to the International Federation of Gynecology and Obstetrics (FIGO) staging system ([@b28-or-40-01-0195],[@b29-or-40-01-0195]). This study was approved by the Ethics Committee of Nagoya University.

Formalin-fixed, paraffin-embedded tissue sections were cut at a thickness of 4 µm. For heat-induced epitope retrieval, deparaffinized sections in 0.01 M citrate buffer (Target Retrieval Solution, pH 6.1; Dako, Tokyo Japan) were heated three times at 90°C for 5 min using a microwave oven. Sections were incubated at 4°C for 12 h with primary antibody (anti-rabbit KIF20A polyclonal, at a 1:100 dilution; Santa Cruz Biotechnology). The sections were rinsed and incubated for 30 min with biotinylated anti-rabbit IgG antibody (cat. no. 424022; Nichirei Biosciences Inc., Tokyo, Japan). The immunoreactive staining was processed using the peroxidase-anti-peroxidase method according to the manufacturer\'s instructions (Dako GmbH, Hamburg, Germany). To detect the reaction, 3,3′-diaminobenzidine tetrachloride (DAB) chromogen solution was used. After rinsing in water for 30 min, the sections were counterstained with hematoxylin and then dehydrated. Finally, they were mounted in mounting medium for examination. The specificity of the antibody was determined using a non-specific immunoglobulin IgG (diluted 1:100; cat. no. sc-2025; Santa Cruz Biotechnology) at the same concentration.

### Evaluation of immunohistochemical staining

For the evaluation of the results of immunohistochemical staining, 10 fields of each specimen were selected and evaluated with both low- (magnification, ×100) and high-power microscopy (magnification, ×400). Two investigators assessed the slides without knowledge of the clinicopathological features and were blinded to each other\'s evaluation. The two investigators were in agreement on all the slides examined. Based on the immunostaining activity, a semi-quantitative score was assigned according to the intensity and area of the stained cells, as previously described ([@b30-or-40-01-0195]). For the evaluation of KIF20A expression, the staining intensity was scored as 0 (negative-weak), 1 (medium), 2 (strong), or 3 (very strong). The percentage of the staining area was scored as 0 (0--10%), 1 (11--50%), and 2 (51--100%) relative to the total tumor area. The sum of the staining intensity and area scores was calculated as the final score (0--5) for KIF20A. Tumors with a final score of 0--1 and 2--5, were classified as showing low and high expression, respectively.

### Survival analyses

The distributions of clinicopathological factors were statistically assessed using the Chi-square test or the Fisher\'s exact test. The progression-free survival (PFS) was defined as the time interval between the date of surgery and the date of the last follow-up or recurrence/progression. The overall survival (OS) was defined as the time interval between the date of surgery and the date of the last follow-up or death from any cause. The survival curves were compared employing the log-rank test. Survival analysis was conducted using the Kaplan-Meier method. The prognostic significance of KIF20A expression concerning other clinicopathological variables was assessed using the univariable and multivariable Cox\'s proportional hazard\'s analyses. All statistical analyses were performed with the JMP Pro Ver. 10.0 (SAS Institute Japan Ltd., Tokyo, Japan). A P\<0.05 was considered to indicate a statistically significant result.

### Statistical analysis

All data are expressed as the mean ± SD. Data were calculated from at least three independent experiments. The significance of differences was analyzed by Student\'s t-test or one-way ANOVA. A value of P\<0.05 was considered to indicate a statistically significant result.

Results
=======

### Patient characteristics

We first explored KIF20A expression and its possible involvement in the oncologic outcome of patients with ovarian CCC using immunohistochemical analysis. Patient characteristics are detailed in [Table I](#tI-or-40-01-0195){ref-type="table"}. The median (range) age was 52 (27--71) years. The distributions of the FIGO stage were 58.1% (25/43) stage I, 18.6% (8/43) stage II, 18.6% (8/43) stage III, and 4.7% (2/43) stage IV. Of all patients, 31 (72.1%) underwent complete surgery with surgical staging, and 37 (86.0%) had no residual tumor at the initial surgery. Thirty-seven patients (86.0%) were administered postoperative chemotherapy. Six patients did not undergo postoperative chemotherapy owing to their strong wishes or severe complications. Of the 43 CCC patients, the distributions of KIF20A staining expression was as follows: 7 (score, 0), 11 (score, 1), 7 (score, 2), 6 (score, 3), 6 (score, 4) and 6 (score, 5). KIF20A immunoexpression was classified into the two scoring groups as described above \[low (score 0--1) and high (score 2--5)\]. Representative images of tissue samples for each immunohistochemical staining score are shown in [Fig. 1](#f1-or-40-01-0195){ref-type="fig"}. For the distribution of age and chemotherapy frequency, there was a significant difference between the two groups ([Table I](#tI-or-40-01-0195){ref-type="table"}).

### Oncologic outcome according to KIF20A expression

The median follow-up duration was 64.9, ranging from 4.3 to 159.3 months in all patients. During this period, 18 patients (41.9%) developed recurrence. The median time to recurrence was 11.5 months. The 5-year PFS and OS rates of all CCC patients were 60.0 and 63.5%, respectively. Patients in the high KIF20A expression group showed poorer PFS and OS than those in the low expression group \[PFS (log-rank: P=0.0443; Cox hazard: P=0.0374) and OS (log-rank: P=0.0478, Cox hazard: P=0.0411), respectively\] ([Fig. 2](#f2-or-40-01-0195){ref-type="fig"}). Confining analysis to stage I patients with CCC, similar prognostic tendencies were observed (PFS: P=0.0484; OS: P=0.0486) ([Fig. 3](#f3-or-40-01-0195){ref-type="fig"}).

### Univariable and multivariable analyses

We subsequently performed univariable and multivariable Cox proportional analyses regarding PFS/OS, including age (≤50 vs. \>50 years), FIGO stage (I+II vs. III+IV), preoperative CA-125 values (≤35 vs. \>35 U/ml), volume of ascites (≤100 vs. \>100 ml), type of surgery (standard surgery with full staging vs. other surgery), residual tumor (yes vs. no), chemotherapy (platinum-based vs. taxane plus platinum) and KIF20A immunoreactivity (low vs. high) ([Table II](#tII-or-40-01-0195){ref-type="table"}). In the univariable analyses, the preoperative CA-125 value, volume of ascites, FIGO stage, residual tumor presence and KIF20A expression were significant prognostic indicators of a poor PFS. In addition, KIF20A expression was found to be a marginally significant prognostic indicator of a poor OS (P=0.0512). In general, age was considered to be an important clinical factor influencing patient survival. On the other hand, the preoperative CA-125 value, volume of ascites, and residual tumor were strongly correlated with the stage. To avoid multicollinearity, we entered the age, stage and KIF20A expression factors into the multivariable analyses. In multivariable analyses, the KIF20A expression was also a significantly independent indicator for PFS and a marginal-significant indicator for OS \[PFS: HR (high vs. low), 5.488; 95% CI, 1.410--24.772 (P=0.0136); OS: HR, 2.835; 95% CI, 0.854--11.035 (P=0.0897)\] ([Table II](#tII-or-40-01-0195){ref-type="table"}).

### KIF20A expression in the deceased ovarian CCC patients

[Table III](#tIII-or-40-01-0195){ref-type="table"} shows the clinical backgrounds of the 17 deceased patients. The high-level expression of KIF20A was observed in 13 of the 17 patients (76.5%). In the majority of deceased patients, the most frequent site of recurrence was the peritoneal cavity and/or distant parenchymal organs (14/17: 82.4%).

### Association between KIF20A expression and the proliferation-promoting effect

We subsequently investigated the role of KIF20A in the malignant characteristics of CCC cells using several *in vitro* experiments. We initially examined the expression of KIF20A in various CCC and non-CCC cells. KIF20A was expressed in RMG-I, RMG-II and ES-2 cells, but lower-level expression of KIF20A was observed in KOC-7C and TOV-21G cells (these lines are all CCC cells). As non-CCC/EOC cells, KIF20A was expressed in SKOV-3 and OV-90 cells ([Fig. 4A](#f4-or-40-01-0195){ref-type="fig"}). We further examined whether KIF20A was associated with the proliferation-promoting effect *in vitro*. ES-2 and SKOV3 cells were successfully transfected with siRNAs (si-KIF20A) ([Fig. 4B](#f4-or-40-01-0195){ref-type="fig"}) and were assessed by the cell proliferation assay (CCK-8 assay) as described above. KIF20A knockdown significantly decreased the cell proliferation ([Fig. 4C](#f4-or-40-01-0195){ref-type="fig"}) (P\<0.05). To further confirm that KIF20A was involved in cell proliferation, we again performed the CCK-8 assay using Paprotrain, which is a cell-permeable acrylonitrile compound that inhibits KIF20A. As a result, treatment with 100 µM of Paprotrain led to an \~50% decrease in the proliferation ability ([Fig. 4D](#f4-or-40-01-0195){ref-type="fig"}) (P\<0.05) in the ES-2 and SKOV3 cells. In addition, we confirmed that this proliferation-inhibitory effect was observed in a concentration-dependent manner ([Fig. 4E](#f4-or-40-01-0195){ref-type="fig"}).

To determine the mitogenic effect of KIF20A, we then performed cell-cycle analysis using ES2 and SKOV3 cells. The distribution of the cell cycle was tested using flow cytometric analysis. As shown in [Fig. 4F](#f4-or-40-01-0195){ref-type="fig"}, the suppression of KIF20A expression led to the increase in the G2/M phase population and decrease in the G1 phase population. This observation suggested that knockdown of KIF20A induced the G2/M arrest (P\<0.05). We finally tested whether the downregulation of KIF20A expression led to the enhanced apoptotic fraction using the apoptosis assay. Consequently, in the si-KIF20A-transfected ES-2 cells, the apoptosis-induced fraction was higher than that in the the control-siRNA transfected ES-2 cells \[12.4±2.3 vs. 5.6±4.9% (P\<0.05), respectively\] ([Fig. 4G](#f4-or-40-01-0195){ref-type="fig"}). These results indicate that KIF20A may be involved in the mitogenic effect in CCC cells.

Discussion
==========

In the present study, we first demonstrated that KIF20A expression was significantly correlated with a poor oncologic outcome in patients with ovarian CCC. Furthermore, multivariate analyses demonstrated that a higher expression of KIF20A was an independent prognostic indicator of a poorer PFS of CCC patients. Up to the present, a number of studies have demonstrated the important association between KIF20A expression and aggressive phenotypes in several solid malignancies. Zhang *et al* ([@b24-or-40-01-0195]) demonstrated that elevated KIF20A expression was associated with a number of clinicopathological factors in cervical squamous cell carcinoma, including HPV infection, stage, recurrence, lymphovascular space involvement, nodal status, and poor outcome in patients with this tumor, and concluded that aberrant KIF20A expression is a novel independent unfavorable prognostic indicator that may be a potential therapeutic target for cervical cancer. Liu *et al* ([@b25-or-40-01-0195]) reported that KIF20A was aberrantly expressed in nasopharyngeal cancer, and that high KIF20A protein expression was significantly correlated with poor 5-year OS and PFS. The cumulative 5-year OS and PFS for the high KIF20A-expressing group were 78.5 and 62.7%, respectively, and 95.9 and 90.8%, respectively, for the low or no KIF20A-expressing group. In addition, Duan *et al* ([@b31-or-40-01-0195]) reported the clinical effect of KIF20A expression in 119 patients with glioma. They demonstrated that patients with positive KIF20A expression showed significantly poorer OS compared with patients with negative KIF20A expression (median, 16.0 vs. 39.0 months, respectively). Our current results are consistent with those of these previous studies. Similarly to patients with EOC, those with CCC show an unfavorable prognosis, principally attributable to its asymptomatic intraperitoneal dissemination with or without distant metastases to parenchymal organs ([@b32-or-40-01-0195]). Our data were obtained from a small number of patients, and therefore, the prognostic significance of KIF20 needs to be confirmed in a larger number of patients. At least, the present findings clarify that the immunoreactive expression of KIF20A may be a critical indicator of a poor prognosis in CCC patients, and its identification may result in the selection of better strategic options.

Our current data indicated that KIF20A participated in the growth of CCC cells. Furthermore, we demonstrated that KIF20A regulates cell division, and the knockdown of KIF20A induced apoptosis and cell cycle arrest via nuclear localization. In addition, the present study showed that the inhibition of KIF20A induced the multinucleation of cells, which ensures the inhibition of cell division. KIF20A is required during mitosis exit for the final step of cytokinesis, and its inhibitor, Paprotrain, inhibits the recruitment of the surviving chromosome passenger proteins and aurora B to the central spindle during the anaphase ([@b33-or-40-01-0195]). A previous report demonstrated that KIF20A plays a crucial role in the proliferation and tumor growth of hepatocellular carcinoma as a novel downstream target of glioma-associated oncogene 2 (Gli2) ([@b26-or-40-01-0195]). This evidence prompted us to hypothesize that the growth-inhibitory effect in KIF20A silencing CCC cells may be partly attributable to the inhibition of activity to drive the cell cycle. Moreover, tumor invasion and migration are representative steps in the peritoneal dissemination of this tumor ([@b34-or-40-01-0195],[@b35-or-40-01-0195]). Stangel *et al* ([@b15-or-40-01-0195]) reported that KIF20A silencing with small interfering RNA molecules resulted in the inhibition of motility and invasion of pancreatic cancer cell lines, as well as the growth-promoting effect of KIF20A. It is possible that KIF20A is involved in these multiple steps of the peritoneal metastasis of CCC. We hope to clarify these unelucidated mechanisms of KIF20A in CCC in our next investigation.

Additionally, CCC patients generally showed a very low chemoresponse rate to platinum-based compounds, leading to intrinsic chemoresistance ([@b9-or-40-01-0195]--[@b36-or-40-01-0195]). In the present study, the majority of patients showing a higher expression of KIF20A died of the disease \[13/17 (76.4%)\]. In general, the remaining chemoresistant clone may be a cause of the high rate of recurrence and/or cancer-related mortality. Thus, one of the mainstream mechanisms leading to patients with KIF20A expression showing an unfavorable clinical outcome may be based on the chemoresistant hallmark as well as the growth-promoting effect of KIF20A. Actually, Khongkow *et al* ([@b22-or-40-01-0195]) revealed that paclitaxel targets the FOXM1-KIF20A axis to drive abnormal mitotic spindle formation and mitotic catastrophe, and that deregulations of FOXM1 and KIF20A expression may be involved in the resistance to paclitaxel. Based on our current result that silencing KIF20A expression induced the upregulation of apoptosis in CCC cells, its knockdown may lead to enhancement of the chemosusceptibility of this tumor, although we did not investigate the direct correlation between KIF20A expression and chemoresistance. Also, we hope to verify this hypothesis in the next study in order to clarify the CCC-specific biological hallmarks.

To the best of our knowledge, the present study is the first to report that the expression of KIF20A was closely associated with a poor oncologic outcome of patients with CCC. The current findings may be based on the growth- and/or chemoresistant-promoting effects of KIF20A, although further investigation is needed to clarify its molecular mechanism. Furthermore, KIF20A could be considered as an ideal cancer-testis antigen and the KIF20A peptide may be a cancer vaccine for pancreatic cancer. A phase I/II clinical trial using a peptide vaccine derived from KIF20A revealed that patients with advanced pancreatic cancer vaccinated with KIF20A-derived peptide had a better prognosis than control patients ([@b37-or-40-01-0195],[@b38-or-40-01-0195]). From this point of view, the present study demonstrated the possibility of using KIF20A-derived peptide vaccine for the treatment of advanced CCC.

In summary, we identified KIF20A as a prognostic indicator and therapeutic target in patients with CCC. However, the detailed functions of KIF20A remain unclear. Particularly, we think that the present study was preliminary because overexpression or restoration assays and animal experiments have not been performed to conclude the possible implication of KIF20A in the proliferation of CCC. Further studies are needed in order to realize therapeutic application. We believe that the mechanistic clarification of KIF20A will help improve treatment for CCC patients by adding criteria for the administration of systematic therapy in the future.
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![Immunoreactive KIF20A expression in ovarian CCC tissues (paraffin sections). Based on the KIF20A immunostaining activity, a semi-quantitative score was assigned according to the intensity and area of the stained cells, as described in the text. (A) Negative-weak (score 0, low); (B) medium (score 1, low); (C) medium (score 3, high); (D) very strong (score 5, high); (magnification, ×100). Scale bars, 100 µm.](OR-40-01-0195-g00){#f1-or-40-01-0195}

![Kaplan-Meier progression-free survival curves for ovarian CCC patients according to the immunoreactivity of KIF20A. (A) PFS. Solid line indicates low KIF20A expression (N=18). Dashed line represents high KIF20A immunoexpression (N=25). Patients with positive KIF20A expression showed a significantly poorer PFS (P=0.0443). (B) OS. Solid line indicates low KIF20A expression (N=18). Dashed line represents high KIF20A immunoexpression (N=25). Patients positive for KIF20A expression showed a significantly poorer OS (P=0.0478). PFS, progression-free survival; OS, overall survival.](OR-40-01-0195-g01){#f2-or-40-01-0195}

![Kaplan-Meier progression-free survival curves for CCC patients with stage I tumors according to the immunoreactivity of KIF20A. (A) PFS. Solid line indicates low KIF20A expression (N=12). Dashed line represents high KIF20A immunoexpression (N=13). Patients positive for KIF20A expression showed a significantly poorer PFS (P=0.0484). (B) OS. Solid line indicates low KIF20A expression (N=12). Dashed line represents high KIF20A immunoexpression (N=13). Patients positive for KIF20A expression showed a significantly poorer PFS (P=0.0486). PFS, progression-free survival; OS, overall survival.](OR-40-01-0195-g02){#f3-or-40-01-0195}

![Association between KIF20A expression and the proliferation-promoting effect. (A) The expression of KIF20A in various CCC or non-CCC cell lines. KIF20A was expressed in ES-2, SKOV-3, OV-90, RMG-I and RMG-II cells. In TOV-21G and KOC-7C cells, the expression of KIF20A was weak. PANC1 (pancreatic cancer cells: positive control), ES-2, RMG-I, RMG-II, TOV-21G and KOC-7C cells (CCC cells) and SKOV3, OV-90 (non-CCC ovarian carcinoma cells) were used. (B) Western blotting and densitometric analyses showing the inhibitory efficacy of KIF20A expressions by siRNA (ES-2 and SKOV3). (C) The effect of KIF20A on cell proliferation in ES2 and SKOV3 cells transfected with KIF20A-siRNA (si-KIF20A) or control siRNA (si-ctrl) using Cell Counting Kit-8 (CCK-8). \*P\<0.05 indicates significance. (D) The proliferation-inhibitory effect of Paprotrain, a cell-permeable acrylonitrile compound that inhibits the kinesin-6 family member KIF20A (time course). \*P\<0.05 indicates significance. (E) The proliferation-inhibitory effect of Paprotrain was observed in a concentration-dependent manner. \*P\<0.05, \*\*P\<0.01 indicate significance. (F) Evaluation of the cell cycle distribution using flow cytometric analysis. Suppression of KIF20A expression resulted in an increase in the G2/M phase population and a decrease in the G1 phase population, suggesting that knockdown of KIF20A induced G2/M arrest (\*P\<0.05). (G) Enhancement of the apoptotic fraction by the downregulation of KIF20A. In the si-KIF20A-transfected cells, the apoptosis-induced fraction was higher than that in the control-siRNA-transfected cells \[(\*P\<0.05), respectively\].](OR-40-01-0195-g03){#f4-or-40-01-0195}

###### 

Relationship between the expression of KIF20A and clinicopathologic parameters.

                                                                      KIF20A expression                           
  ------------------------------------------------------------------- ------------------- ---- ------ ---- ------ --------
  Total no. of cases                                                  43                  18          25          
  Age (years)                                                                                                     
    ≤50                                                               21                  14   77.8   7    28.0   0.001
    \>50                                                              22                  4    22.2   18   72.0   
  FIGO stage                                                                                                      
    I                                                                 25                  12   66.7   13   52.0   0.697
    II                                                                8                   3    16.7   5    20.0   
    III                                                               8                   2    11.1   6    24.0   
    IV                                                                2                   1    5.6    1    4.0    
  Preoperative CA-125 value (U/ml)                                                                                
    ≤35                                                               32                  12   66.7   20   80.0   0.323
    \>35                                                              11                  6    33.3   5    20.0   
  Ascites volume (ml)                                                                                             
    \<100                                                             23                  11   61.1   12   48.0   0.245
    100--1,000                                                        5                   0    0.0    5    20.0   
    \>1,000                                                           7                   3    16.7   4    16.0   
    NA                                                                8                   4    22.2   4    16.0   
  Surgery                                                                                                         
    Standard surgery + full staging                                   31                  14   77.8   17   68.0   0.417
    Standard surgery^[a](#tfn2-or-40-01-0195){ref-type="table-fn"}^   6                   2    11.1   4    16.0   
    USO/BSO ± OM                                                      2                   1    5.6    1    4.0    
    Debulking surgery                                                 1                   1    5.6    0    0.0    
    Exploratory                                                       3                   0    0.0    3    12.0   
  Residual tumor                                                                                                  
    No                                                                37                  17   94.4   20   80.0   0.178
    Yes                                                               6                   1    5.6    5    20.0   
  Chemotherapy                                                                                                    
    None                                                              6                   5    27.8   1    4.0    0.0149
    Platinum-based                                                    10                  6    33.3   4    16.0   
    Taxane plus platinum                                              27                  7    38.9   20   80.0   

KIF20A, Kinesin family member 20A; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125; USO, unilateral salpingooophorectomy; BSO, bilateral salpingooophorectomy.

Standard surgery, including hysterectomy, bilateral salpingo-oophorectomy, with or without omentectomy (OM).

###### 

Univariable and multivariable analyses.

                                     PFS                      OS                                                                                                   
  ---------------------------------- ------------------------ -------- ------------------------ -------- ------------------------ -------- ----------------------- --------
  Age (years)                                                                                                                                                      
    ≤50                              Referent                 0.619    Referent                 0.1984   Referent                 0.567    Referent                0.9678
    \>50                             1.265 (0.498--3.324)              0.454 (0.141--1.540)              1.322 (0.502--3.542)              1.022 (0.348--3.225)    
  Preoperative CA-125 value (U/ml)                                                                                                                                 
    ≤35                              Referent                 0.0052   --                                Referent                 0.0078   --                      
    \>35                             8.163 (1.671--147.183)                                              7.646 (1.553--138.162)                                    
  Ascites volume (ml)                                                                                                                                              
    ≤100                             Referent                 0.0054   --                                Referent                 0.0079   --                      
    \>100                            4.558 (1.570--14.866)                                               4.501 (1.491--14.981)                                     
  FIGO stage                                                                                                                                                       
    I--II                            Referent                 0.0031   Referent                 0.0014   Referent                 0.0106   Referent                0.0111
    III--IV                          4.564 (1.720--11.731)             5.696 (2.018--116.282)            3.970 (1.405--10.280)             3.978 (1.397--10.865)   
  Surgery                                                                                                                                                          
    Standard surgery+full staging    Referent                 0.3686   --                                Referent                 0.457    --                      
    Other surgery                    1.589 (0.552--4.097)                                                1.505 (0.477--4.076)                                      
  Residual tumor                                                                                                                                                   
    No                               Referent                 0.0229   --                                Referent                 0.0302   --                      
    Yes                              3.888 (1.233--10.472)                                               4.227 (1.170--12.241)                                     
  Chemotherapy                                                                                                                                                     
    Platinum-based                   Referent                 0.830    --                                Referent                 0.9344   --                      
    Taxane plus platinum             0.890 (0.329--2.808)                                                0.956 (0.344--3.060)                                      
  KIF20A expression                                                                                                                                                
    Low                              Referent                 0.0374   Referent                 0.0136   Referent                 0.0512   Referent                0.0897
    High                             2.979 (1.061--10.562)             5.488 (1.410--24.772)             2.833 (0.995--10.117)             2.835 (0.854--11.035)   

KIF20A, Kinesin family member 20A; PFS, progression-free survival; OS, overall survival; HR, hazard ratio; 95% CI, 95% confidence interval; CA-125, cancer antigen 125; FIGO, International Federation of Gynecology and Obstetrics.

###### 

Clinical features and KIF20A immunoexpression in the deceased ovarian CCC patients.

  Case   Age (years)   KIF20A expression   FIGO stage   Ascites volume (ml)   CA-125 (U/ml)   Chemotherapy   Residual tumor   Recurrence site    Time to relapse (mo)   OS (mo)
  ------ ------------- ------------------- ------------ --------------------- --------------- -------------- ---------------- ------------------ ---------------------- ---------
  1      49            High                IIIc         ≤100                  54              P-based        None             Pelvis             6.7                    88.2
  2      49            High                Ic           ≥1,000                373             P-based        None             Distant            41.7                   64.7
  3      52            High                Ic           100--1,000            41              P-based        None             PC + distant       76.8                   103.3
  4      53            Low                 IIc          ≤100                  60              None           None             PC                 6.6                    10.6
  5      40            High                Ic           100--1,000            55              TP             None             PC+RPN             7.1                    13.7
  6      38            Low                 IIb          ≤100                  52              TP             None             PC                 13.3                   24.1
  7      38            High                IIc          ≤100                  328             TP             None             Pelvis             16.4                   40.6
  8      49            Low                 Ic           100--1,000            67              P-based        None             Pelvis + distant   9.1                    37.5
  9      27            Low                 IV           ≤100                  NA              P-based        None             PC                 8.4                    8.8
  10     52            High                Ic           ≤100                  10              TP             None             Distant            29.4                   46.9
  11     54            High                IV           ≥1,000                890             TP             ≥5 cm            Distant            8.9                    8.9
  12     53            High                Ic           ≤100                  111             TP             None             PC + distant       10.0                   14.3
  13     55            High                IIIc         ≤100                  NA              TP             ≥5 cm            PC                 9.1                    9.1
  14     55            High                IIIc         100--1,000            920             TP             None             PC                 17.9                   37.3
  15     39            High                Ia           ≤100                  53              TP             None             Pelvis             19.6                   49.7
  16     59            High                IIIc         ≥1,000                3,149           TP             None             PC                 39.4                   39.4
  17     58            High                IIIc         ≥1,000                1,012           TP             ≤1 cm            PC                 4.3                    4.3

KIF20A, Kinesin family member 20A; CCC, clear-cell carcinoma; FIGO, International Federation of Gynecology and Obstetrics; CA-125, cancer antigen 125; OS, overall survival; P-based, conventional platinum-based chemotherapy; TP, taxane plus platinum; PC, peritoneal cavity; RPN, retroperitoneal lymph node; Distant, distant parenchymal organ; NA, not applicable.
